Selection of drug combinations in clinical practice: Current and future perspectives

Antiepileptic Drugs: Combination Therapy and Interactions

Volumn , Issue , 2005, Pages 421-440

  Majkowski, Jerzy ^a  

^a Foundation of Epileptology   (Poland)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 35348907382     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1017/CBO9780511545023.025     Document Type: Chapter

References (115)

1. Arroyo S, Brodie MJ, Avanzini G, et al. Is refractory epilepsy preventable? Epilepsia 2002; 43: 437–444.
2. Arzimanoglou A, Gerardin V, Moszkowski J, et al. Lamotrigine in patients with childhood onset intractable epilepsy. Epilepsia 1993; 34(Suppl. 6): 113.
3. Baldy-Moulinier M, Civanis A, D’Urso S, et al. Therapeutic strategies against epilepsy in Mediterranean countries: a report from an international collaborative surgery. Seizure 1998; 7: 513–520.
4. Benetello P, Furlanut M, Baraldo M, et al. Therapeutic drug monitoring of lamotrigine in patients suffering from resistant partial seizures. Eur Neurol 2002; 48: 200–203.
5. Besag FMC, Panayiotopoulos C, Chivers F, et al. Therapeutic interaction of lamotrigine with valproate and suximides. Epilepsia 1995; 36(Suppl. 3): 116.
6. Besag FMC, Berry DJ, Pool F, et al. Carbamazepine toxicity with lamotrigine: pharmacokinetic or pharmacodynamic interactions? Epilepsia 1998; 39: 183–187.
7. Bisulli F, Baruzzi A, Rosati A, et al. Efficacy of lamotrigine add-on therapy in severe partial epilepsy in adults with drop seizures and secondary bilateral synchrony on EEG. Epileptic Disord 2001; 3: 151–156.
8. Biton V, Vasquez B, Sachedo RC, et al. Adjunctive tiagabine compared with phenytoin and carbamazepine in multicenter, double-blind trial of complex partial seizures. Epilepsia 1998; 39(Suppl. 6): 125–126.
9. Bourgeois BFD. Antiepileptic drug combinations and experimental background: the case of phenobarbital and phenytoin. Naunyn Schmiedebergs Arch Pharmacol 1986; 333: 406–411.
10. Bourgeois BFD. Combination of valproate and ethosuximide: Antiepileptic and neurotoxic interactions. J Pharmacol Ther 1988; 247: 1128–1132.
11. Brodie MJ, Yuen AC, 105 Study Group. Lamotrigine substitution study: evidence for synergism with sodium valproate. Epilepsy Res 1997; 26: 423–432.
12. Brodie MJ, Mumford JP for the 012 Study Group. Double blind substitution of vigabatrin and valproate in carbamazepine-resistant partial epilepsy. Epilepsy Res 1999; 40: 199–205.
13. Camfield PR, Camfield CS. Antiepileptic drug therapy: when is epilepsy truly intractable? Epilepsia 1996; 37(Suppl. 1): 60–65.
14. Castillo S, Schmidt DB, White S. Oxcarbazepine add-on for drug-resistant partial epilepsy. Cochrane Database Syst Rev 2000; CD002028.
15. Cereghino JJ, Brock JT, van Meter JC, et al. The efficacy of carbamazepine combinations in epilepsy. Clin Pharmacol Ther 1975; 18: 733–741.
16. Chadwick DW, Marson AG. Zonisamide add-on for drug-resistant partial epilepsy Cochrane Rev. The Cochrane Library 2003; Issue, 2. Oxford: Update Software.
17. Chaisewikul R, Baillie N, Marson AG. Calcium antagonists as an add-on therapy for drugresistant epilepsy. Cochrane Rev. Cochrane Library 2001a; Issue 4, Oxford: Update Software.
18. Chaisewikul R, Privitera MD, Hutton JL, et al. Levetiracetam add-on for drug-resistant localization related (partial) epilepsy. Cochrane Database Syst Rev 2001b; CD001901.
19. Coatsworth JJ. Studies on the clinical efficacy of marketed antiepileptic drugs. NIH PHS USDHEW Bethesda Md 1971; 5: 393.
20. Czuczwar SJ. Experimental background for synergistic and additive effects of antiepileptic drugs. Epileptologia 1998; 6(Suppl. 2): 21–29.
21. Czuczwar SJ, Borowicz KK. Polytherapy in epilepsy: the experimental evidence. Epilepsy Res 2002; 52: 15–23.
22. Czuczwar SJ, Gasior M, Janusz W, et al. Influence of flunarizine, nicardipine and nimodipine on the anticonvulsant activity of different antiepileptic drugs in mice. Neuropharmacology 1992; 31: 1179–1183.
23. Dean JC, Penry JK. Carbamazepine/valproate therapy in 100 patients with partial seizures failing carbamazepine monotherapy: long-term follow-up. Epilepsia 1988; 29: 687.
24. Deckers CLP, Czuczwar SJ, Hekster YA, et al. Selection of antiepileptic drug polytherapy based on mechanism of action: the evidence reviewed. Epilepsia 2000; 41: 1364–1374.
25. Deckers CLP, Hekster YA, Keyser A, et al. Monotherapy versus polytherapy for epilepsy: A multicenter double-blind randomised study. Epilepsia 2001; 42: 1387–1394.
26. Deckers CLP, Genton P, Sills GJ, et al. Current limitations of antiepileptic drug therapy; a conference review. Epilepsy Res 2003; 53: 1–17.
27. Delanty N, French JA, Williams SF. Lamotrigine and topiramate combination therapy: experience from postmarking surveillance. Epilepsia 1998; 39(Suppl. 6): 131.
28. Delgado-Escueta AV, Mattson RH, Smith DB, et al. Principles in designing clinical trials for antiepileptic drugs. Neurology 1983; 33(Suppl. 1): 8–13.
29. De Romanis F, Sopranzi N. Lamotrigine in the therapy of resistant epilepsy. Clin Therapeutica 1999; 150: 279–282.
30. Doychinov D. Didepil for the treatment of epilepsy. In Epilepsy: A Clinical and Experimental Research. J. Majkowski, ed. Monogr Neural Sci. Basel: S. Karger, 1980: 112–118.
31. Duncan JS. Principles of treatment of patients with chronic active epilepsy. In The Treatment of Epilepsies. S. Shorvon, F. Dreifuss, D. Fish, D. Thomas, eds. Oxford: Blackwell Science, 1996: 177–190.
32. Ebert U, Rundfeldt C, Lehmann H, et al. Characterization of phenytoin-resistant kindled rats, a new model of drug-resistant partial epilepsy: influence of experimental and environmental factors. Epilepsy Res 1999, 33: 199–215.
33. Elger CE, Fernandez, G. Options after the first antiepileptic drug has failed. Epilepsia 1999; 40(Suppl. 6): 9–12.
34. Elices E, Arroyo S. Is drug resistant partial epilepsy progressive? Rev Neurol 2002; 34: 505–510.
35. Elwes RDC, Johnson AL, Reynolds EH. The course of untreated epilepsy. Br Med J 1988; 29: 948–950.
36. Eriksson AS, Nergardh A, Hoppu K. The efficacy of lamotrigine in children and adolescent with refractory generalized epilepsy: a randomized, double-blind, crossover study. Epilepsia 1998; 39: 495–501.
37. Feely M, Gibson J. Intermittent clobazam for catamenial epilepsy: tolerance avoided. J Neurol Neurosurg Psychiatr 1984; 47: 1279–1282.
38. Ferrie CD, Panayiotopoulos CP. Therapeutic interactions of lamotrigine and sodium valproate in intractable myoclonic epilepsy. Seizure 1999; 3: 1375–1376.
39. Ferrendelli JA. Rational polypharmacy. Epilepsia 1995; 36(Suppl. 2): 115–118.
40. Frey M, Kanner AM. Do lamotrigine and valproic acid have an additive anticonvulsant effect. Epilepsia 1999; 40(Suppl. 7): 144.
41. Fröscher W. Synergistic and additive effects of antiepileptic drugs in epileptic patients. Epileptologia 1998; 6(Suppl. 2): 31–42.
42. Fröscher W. Clinical experience with synergistic and additive effects of antiepileptic drugs in epileptic patients – new developments. Epileptologia 2000; 8: 221–227.
43. Fröscher W, Stodl K-D, Hoffmann F. Kombinationsbehandlung mit Carbamazepin und Valproinsäure bei Problemfällen einer Epilepsie-Ambulanz. Arzneim Forsch 1984; 34: 910–914.
44. Fröscher W, Rauber A, Rothmeier J, et al. Vigabatrin bei pharmakoresistenten Epilepsien. Akt Neurol 1992; 19: 48–49.
45. Gorman WP, Cooper R, Pocock P, et al. A comparison of primidone, propranolol, and placebo in essential tremor, using quantitative analysis. J Neurol Neurosurg Psychiatr 1986; 49: 64–68.
46. Guberman A, Neto W, Gassmann-Mayer C, EPAJ-119 Study Group. Low-dose topiramate in adults with treatment-resistant partial-onset seizures. Acta Neurol Scand 2002; 106: 183–189.
47. Hakkarainen H. Carbamazepine vs diphenylhydatoin vs their combination in adult epilepsy. Neurology 1980; 30: 354.
48. Jette NJ, Marson AG, Hutton JL. Topiramate add-on for drug-resistant partial epilepsy. Cochrane Database Syst Rev 2002; CD001417.
49. Jêdrzejczak J, Dlawichowska E, Owczarek K, et al. Effect of vigabatrin addition on carbamazepine blood serum levels in patients with epilepsy. Epilepsy Res 2000; 39: 115–120.
50. Jêdrzejczak J, Leñska-Mieciek M, Tomik BJ. The dynamics of natural, undiagnosed epilepsy of many years’ duration – diagnostic difficulties. Three case studies. Epileptologia 2002; 10: 163–174.
51. Krämer G, Theisohn M, von Unruh GE, et al. Carbamazepine-danazol drug interaction: its metabolism examined by a stable isotope technique. Ther Drug Monit 1986; 8: 387–392.
52. Kugler St. L, Sachedo RC, Wenger EC, et al. Efficacy of combination topiramate and lamotrigine in refractory epilepsy in children. Epilepsia 1997; 38(Suppl. 8): 192–193.
53. Kwan P, Brodie MJ. Early identification of refractory epilepsy. Engl J Med 2000; 342: 314–319.
54. Leach JP, Brodie MJ. Synergism with GABA-ergic drugs in refractory epilepsy (letter). Lancet 1994; 343: 1650.
55. Leppik LE, Wolff DL. Antiepileptic medication interactions. Neurologic Clinics 1993; 11: 905–921.
56. Löscher W. Animal models of drug-resistant epilepsy. Novartis Found Symp 2002; 243: 149–159.
57. Löscher W, Ebert U. Basic mechanisms of seizure propagation: targets for rational drug design and rational polypharmacy. Epilepsy Res Suppl 1996; 11: 3–7.
58. Löscher W, Leppik IE. Critical re-evaluation of previous preclinical strategies for the discovery and the development of new antiepileptic drugs. Epilepsy Res 2002; 50: 17–20.
59. Luszczki JJ, Swiader M, Parada-Turska J, et al. Tiagabine synergistically interacts with gabapentin in the electroconvulsive threshold test in mice. Neuropsychopharmacology 2003; 28: 1817–1830.
60. Lu¨ders HO. National Institutes of Health Consensus Conference. Surgery for epilepsy. J Am Med Assoc 1990; 264: 729–733.
61. Lysakowska-Sernicka K, Majkowski J, Biliñska-Nigot B. Antiepileptic and side effects of Didepil. In Epilepsy: A Clinical and Experimental Research. J. Majkowski, ed. Monogr Neural Sci. Basel: S. Karger, 1980: 119–123.
62. Majkowski J. Drug effects on after discharge and seizure threshold in lissencephalic ferrets: an epilepsy model for drug evaluation. Epilepsia 1983; 24: 678–685.
63. Majkowski J. Drug resistant epilepsy and rational polytherapy in the era of new antiepileptic drug. Epileptologia 1996; 4: 281–293.
64. Majkowski J. Natural course of epileptogenesis: from partial simple to partial complex seizures. A case report. Epileptologia 1998; 6: 99–112.
65. Majkowski J. Kindling: clinical relevance for epileptogenicity in humans. In Advances in Neurology. H. Stefan, F. Andermann, P. Chauvel, S. Shorvon, eds., Philadelphia: Lippincott Williams & Wilkins, 1999; 81, 105–113.
66. Majkowski J. The natural progression of epileptogenesis: from partial simple visual seizure to complex and secondary generalised seizures. A case study. Epileptologia 2000; 7: 47–58.
67. Majkowski J, Lee MH, Kozlowski PB, et al. EEG and seizure threshold in normal and lissencephalic ferrets. Brain Res 1984; 307: 29–38.
68. Majkowski J, Danneberg P, Knappen F. Differences in antiepileptic drug efficacy in hippocampal kindled normal and microcephalic rats. Brain Res 1986; 386: 325–331.
69. Majkowski J, Sidor K, Wendorff J, et al. Prophylaxis and control of febrile convulsion (FC) by rectal administration of diazepam. Prospective study. Preliminary Report. Epileptologia 1995; 3: 111–120.
70. Majkowski J, Kacinski M, Jedrzejazak J, et al. Pharmacological treatment of epilepsy in Poland 2000–2001. Multicenter Prospective Study of 6195 Patients. Epideplogia 2005; 13: In press
71. Marroni M, Marchi N, Cucullo L, et al. Vascular and parenchymal mechanisms in multiple drug resistance: a lesson from human epilepsy. Curr Drug Targets 2003; 4: 297–304.
72. Marson AG, Hutton JL, Leach JP, et al. Levetiracetam, oxcarbazepine and zonisamide for drug resistant localisation related epilepsy: a systemic review. Epilepsy Res 2001; 46: 259–270.
73. Masuda Y, Utsui Y, Shiraishi Y, et al. Evidence for a synergistic interaction between phenytoin and phenobarbital in experimental animals. J Pharmacol Exp Ther, 1981; 217: 805–811.
74. Mattson RH. Drug treatment of partial epilepsies. Adv Neurol 1992; 57: 643–650.
75. Mattson RH, Cramer JA. Crossover from polytherapy to monotherapy in primary generalised epilepsy. Amer J Med 1988; 84(Suppl. 1A): 23–38.
76. Mattson RH, Klein PE, Caldwell BV, et al. Medroxyprogesterone treatment of women with uncontrolled seizures. Epilepsia 1982; 23: 436–437.
77. Mattson RH, Cramer JA, Delgado-Escueta AV, et al. A design for the prospective evaluation of the efficacy and toxicity of antiepileptic drugs in adults. Neurology 1983; 33(Suppl. 1): 14–25.
78. Muri L, Judice A. Vigabatrin as first add-on treatment in carbamazepine-resistant epilepsy patients. Acta Neurol Scand 1995; 62(Suppl. 1): 40–42.
79. Ohtsuka Y, Ogino T, Amano R, et al. Rational treatment of refractory epilepsy in childhood. Jpn J Psychiatr Neurol 1988; 42: 443–447.
80. Panayiotopoulos CP, Ferrie CD, Knott C, et al. Interaction of lamotrigine with sodium valproate (letter). Lancet 1993; 341: 445.
81. Patsalos PN, Perucca E. Clinically important drug interactions in epilepsy: general features and interactions between antiepileptic drugs. Lancet Neurol 2003; 2: 347–356.
82. Patsalos PN, Fröscher W, Pisani F, et al. The importance of drug interactions in epilepsy therapy. Epilepsia 2002; 43: 365–385.
83. Pereira J, Marson AG, Hutton JL. Tiagabine add-on for drug-resistant partial epilepsy. Cochrane Database Syst Pev 2002; CD001908.
84. Pippenger CE, Penry JK, White BG, et al. Interlaboratory variability in determination of plasma antiepileptic drug concentrations. Arch Neurol 1976; 33: 351–355.
85. Pisani F, Di Perri R, Perucca E, et al. Interaction of lamotrigine with sodium valproate. Lancet 1993; 341: 1224.
86. Pisani F, Oteri G, Russo MF, et al. The efficacy of valproate–lamotrigine comedication in refractory complex partial seizures: evidence for pharmacodynamic interactions. Epilepsia 1999a; 40: 1141–1146.
87. Pisani F, Oteri G, Antonino F, et al. Complete seizure control following gabapentin–lamotrigine comedication. Epilepsia 1999b; 40(Suppl. 2): 253–254.
88. Potschka H, Fedrowitz M, Löscher W. Brain access and anticonvulsant of carbamazepine, lamotrigine, and felbamate in ARCC2/MRP2 – deficient TR-rats. Epilepsia 2003a; 44: 1479–1486.
89. Potschka H, Fedrowitz M, Löscher W. Multidrug resistance protein MRP2 contributes to blood–brain barrier function and restricts antiepileptic drug activity. J Pharmacol Exp Ther 2003b; 306: 124–131.
90. Proper EA, Hoogland G, Kappen SM, et al. Distribution of glutamate transporters in the hippocampus of patients with pharmaco-resistant temporal lobe epilepsy. Brain 2002; 125: 32–43.
91. Ramaratnam S, Marson AG, Baker GA. Lamotrigine add-on for drug-resistant partial epilepsy. Cochrane Review. Cochrane Library 2003; Issue 4. Oxford: Update Software.
92. Remy S, Gabriel S, Urban BW, et al. A novel mechanism underlying drug resistance in chronic epilepsy. Ann. Neurol 2003; 53: 469–479.
93. Reynolds EH, Shorvon SD. Monotherapy or polytherapy for epilepsy? Epilepsia 1981; 22: 1–10.
94. Ribacoba Montero R, Salas Puig X. Efficacy and tolerability of long term topiramate in drug resistant epilepsy in adults. Rev Neurol 2002; 34: 101–105.
95. Richens A. Drug level monitoring: the importance of quality control. In Epilepsy: A Clinical and Experimental Research. J. Majkowski, ed. Monogr Neural Sci 5. Basel: S. Karger, 1980: 176–182.
96. Robinson MK, Black AB, Schapel GS, et al. Combined gamma-vinyl-GABA (vigabatrin) and lamotrigine therapy in management of refractory epilepsy. Epilepsia 1993; 34(Suppl. 2): 109.
97. Rowan AJ, Meijer JWA, de Beer-Pawlikowski N, et al. Valproate–ethosuximide combination therapy for refractory absence seizures. Arch Neurol 1983; 40: 797–802.
98. Sälke-Kellermann RA, May T, Boenigk HE. Influence of ethosuximide on valproic acid serum concentrations. Epilepsy Res 1997; 26: 345–349.
99. Schapel GJ, Black AB, Lam EL, et al. Combination vigabatrin and lamotrigine therapy for intractable epilepsy. Seizure 1996; 5: 51–56.
100. Schmidt D. Two antiepileptic drugs for intractable epilepsy with complex partial seizures. J Neurol Neurosurg Psychiatr 1982; 45: 1119–1124.
101. Schmidt D, Gram L. Monotherapy versus polytherapy in epilepsy. A reappraisal. CNS Drugs 1995; 3: 194–208.
102. Seegers U, Potschka H, Löscher W. Expression of the multidrug transporter P-glycoprotein in brain parenchyma of amygdala-kindled rats. Epilepsia 2002; 43: 675–684.
103. Shorvon S, Reynolds EH. Reduction in polypharmacy for epilepsy. Br Med J 1979; 2: 1023–1025.
104. Siddiqui A, Kerb R, Weale ME, et al. Association of multidrug resistance in epilepsy with a polymorphism in the drug-transporter gene ABCB1. New Engl J Med 2003; 348: 1442–1448.
105. Sills GJ, Thompson GT, Forrest G, et al. Lack of experimental interaction between vigabatrin and lamotrigine. Epilepsia 1993; 34(Suppl. 6): 92.
106. Sisodiya SM. Mechanisms of antiepileptic drug resistance. Curr Opin Neurol 2003; 16: 197–201.
107. Sisodiya SM, Lin W-R, Harding BN, et al. Drug resistance in epilepsy: expression of drug resistance proteins in common causes of refractory epilepsy. Brain 2002; 1: 22–31.
108. Stephen LJ, Sills GJ, Brodie MJ. Lamotrigine and topiramate may be a useful combination. Lancet 1998; 351: 958–959.
109. Stewart J, Hughes E, Reynolds EH. Lamotrigine for generalized epilepsies (letter). Lancet 1992; 340: 1223.
110. Stolarek I, Blacklaw J, Thompson GG, et al. Gamma-vinyl-GABA (vigabatrin) and lamotrigine: synergism in a refractory epilepsy? Epilepsia 1993; 34(Suppl. 2): 108–109.
111. Tanganelli P, Regesta G. Vigabatrin vs carbamazepine monotherapy in newly diagnosed focal epilepsy: a randomised response conditional cross-over study. Epilepsy Res 1996; 25: 257–262.
112. Walker JE, Koon R. Carbamazepine versus valproate versus combined therapy for refractory partial complex seizures with secondary generalization. Epilepsia 1988; 29: 693.
113. Warner T, Patsalos PN, Prevett M, et al. Lamotrigine-induced carbamazepine toxicity: an interaction with carbamazepine-10, 11-epoxide. Epilepsy Res 1992; 11: 147–150.
114. Willmore LJ, Shu V, Vallin B, the M 88–194 Study Group. Efficacy and safety of add-on divalproex sodium in the treatment of complex partial seizures. Neurology 1996; 46: 49–53.
115. Yahr MD, Sciarra D, Carter S. Evaluation of standard anticonvulsant therapy of 319 patients. J Am Med Assoc 1952; 150: 663–667.